TIRZ (GLP-2) 10 mg
research-grade
lyophilized peptide powder
supplied in a glass vial. This compound, also referred to as
LY3298176,
is an incretin peptide analog studied as a dual agonist at the GIP (glucose-dependent insulinotropic polypeptide) and GLP-1
(glucagon-like peptide-1) receptors in experimental metabolic research models.
Research Use Only:
All products are intended exclusively for laboratory and scientific research. Not for human or veterinary use.
Purity
High-purity research grade
Form
Lyophilized peptide powder
Content
10 mg TIRZ (GLP-2) per vial
Packaging
Glass vial with sterile closure
Storage
Store lyophilized at 2–8 °C (desiccated, protect from light)
Molecular formula
C225H348N48O68
Molecular weight
~4813.5 g·mol⁻¹
Sequence / structure
Tyr-{Aib}-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-{Aib}-Leu-Asp-Lys-{diacid-C20-γGlu-(AEEA)2}-Ala-Ala-Gln-{Aib}-Ala-Phe-Ile-Glu-Tyr-Leu-Leu-Glu-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2
In laboratory workflows, lyophilized research peptides are typically handled with suitable sterile diluents such as bacteriostatic water (BAC).
For a compatible research-only solvent, see
Bacteriostatic water – 10 ml
.
Research Overview
TIRZ (GLP-2), also known as LY3298176, is a synthetic incretin peptide analog investigated as a dual agonist at the GIP and GLP-1 receptors.
In experimental in vitro and in vivo models it is used to explore how concurrent activation of these incretin pathways affects glucose handling,
insulin secretion, glucagon regulation, gastric emptying, appetite-related signaling and broader metabolic endpoints.
Primary Research Areas
-
Dual GIP and GLP-1 receptor agonism:
used in studies assessing combined activation of GIP and GLP-1 receptors and its impact on incretin signaling cascades in metabolic research models.
-
Glucose control and insulin sensitivity:
applied in experimental systems examining insulin secretion, glucagon suppression, glycemic excursions and insulin sensitivity under controlled
laboratory conditions.
-
Body weight and adiposity models:
investigated in preclinical models of body weight regulation, adipose tissue remodeling and energy balance in the context of incretin pathway modulation.
-
Appetite regulation and gastric emptying:
used to study satiety signaling, food intake behavior and gastric emptying rate in animal and cellular models related to appetite control.
-
Cardiometabolic health markers:
included in broader cardiometabolic research evaluating lipid parameters, inflammatory markers and vascular endpoints associated with incretin-based modulation.
